By SPC News Staff
The FDA approved donanemab-azbt (Kisunla, Lilly) injection for the treatment of Alzheimer’s disease. Treatment with donanemab-azbt should be initiated in patients who have mild cognitive impairment or mild dementia stage of disease, the groups for whom treatment was studied in the clinical trials.
Administered as an IV infusion every four weeks, donanemab-azbt is the first amyloid plaque−targeting therapy that used a limited-treatment time based on amyloid plaque